Literature DB >> 8597956

Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia.

E A Garcia-Zepeda1, M E Rothenberg, R T Ownbey, J Celestin, P Leder, A D Luster.   

Abstract

Eotaxin is an eosinophil-specific chemoattractant that has been recently identified in rodent models of asthma and host response against tumors. To determine whether a similar molecule might play a role in human inflammatory diseases characterized by eosinophilia, we isolated the human eotaxin gene. We demonstrate that human eotaxin is an early response gene of cytokine-stimulated epithelial and endothelial cells, and is induced in peripheral blood eosinophils by interleukin-3. Eotaxin is directly chemotactic for eosinophils, but not mononuclear cells or neutrophils. Eotaxin messenger RNA accumulates markedly in the lesions of patients with inflammatory bowel disease (ulcerative colitis and Crohn's disease), but not in the lesions of patients with diverticulitis. These results now provide a mechanism involving eotaxin to explain the eosinophil infiltration seen in a variety of human disease; as such, an eotaxin antagonist may be a novel therapy for certain human diseases characterized by tissue eosinophilia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8597956     DOI: 10.1038/nm0496-449

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  139 in total

Review 1.  Eotaxin and asthma: some answers, more questions.

Authors:  C J Corrigan
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

Review 2.  Slit proteins, potential endogenous modulators of inflammation.

Authors:  Necat Havlioglu; Liya Yuan; Hao Tang; Jane Y Wu
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

3.  Increased expression of chemokine receptor CCR3 and its ligands in ulcerative colitis: the role of colonic epithelial cells in in vitro studies.

Authors:  P Manousou; G Kolios; V Valatas; I Drygiannakis; L Bourikas; K Pyrovolaki; I Koutroubakis; H A Papadaki; E Kouroumalis
Journal:  Clin Exp Immunol       Date:  2010-11       Impact factor: 4.330

4.  Secretion of wound healing mediators by single and bi-layer skin substitutes.

Authors:  Manira Maarof; Jia Xian Law; Shiplu Roy Chowdhury; Khairul Anuar Khairoji; Aminuddin Bin Saim; Ruszymah Bt Hj Idrus
Journal:  Cytotechnology       Date:  2016-01-14       Impact factor: 2.058

5.  The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel Disease: New Insights and Possible Therapeutic Implications.

Authors:  Tomer Adar; Shimon Shteingart; Ami Ben-Ya'acov; Ariella Bar-Gill Shitrit; Dan M Livovsky; Shimrit Shmorak; Mahmud Mahamid; Bernardo Melamud; Fiona Vernea; Eran Goldin
Journal:  Dig Dis Sci       Date:  2016-02-13       Impact factor: 3.199

6.  Eotaxin expression in Sephadex-induced lung injury in rats.

Authors:  R F Guo; P A Ward; J A Jordan; M Huber-Lang; R L Warner; M M Shi
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

7.  CCL11 (Eotaxin-1) Levels Predict Long-Term Functional Outcomes in Patients Following Ischemic Stroke.

Authors:  Meaghan Roy-O'Reilly; Rodney M Ritzel; Sarah E Conway; Ilene Staff; Gilbert Fortunato; Louise D McCullough
Journal:  Transl Stroke Res       Date:  2017-06-21       Impact factor: 6.829

8.  The role of eosinophils in inflammatory bowel disease.

Authors:  S Al-Haddad; R H Riddell
Journal:  Gut       Date:  2005-12       Impact factor: 23.059

9.  Eotaxin increases monolayer permeability of human coronary artery endothelial cells.

Authors:  Md Saha Jamaluddin; Xinwen Wang; Hao Wang; Cubas Rafael; Qizhi Yao; Changyi Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-09-24       Impact factor: 8.311

Review 10.  Pulmonary involvement and allergic disorders in inflammatory bowel disease.

Authors:  Nikolaos E Tzanakis; Ioanna G Tsiligianni; Nikolaos M Siafakas
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.